Novel GPR37L1 agonist reduces neuropathic pain in mouse models

Researchers used virtual screening and molecular dynamics simulations to identify P06, a small-molecule agonist of GPR37L1, a glia-selective receptor expressed in astrocytes and satellite glial cells. In mouse models of chemotherapy-induced peripheral neuropathy and spared nerve injury, a single intrathecal injection of P06 produced long-lasting inhibition of mechanical allodynia, an effect abolished in Gpr37l1 knockout mice, and P06 also reduced nerve injury-induced reactive gliosis and suppressed paclitaxel-induced Interleukin-1beta release in satellite glial cells. The study reports that these findings establish GPR37L1 as a glia-specific therapeutic target for neuropathic pain.

Most relevant for: Preclinical researchers and clinicians interested in chemotherapy-induced peripheral neuropathy and nerve injury-related neuropathic pain.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.